System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Maria-Victoria Mateos is an expert in Hematology at Centro de Investigación del Cáncer (Spain). As of October 2026, ScienceLeadR ranks Maria-Victoria Mateos in the top 1% of experts worldwide for Paraproteinemias, Multiple Myeloma and Hemostatic Disorders. Maria-Victoria Mateos has authored 1,299 publications, the most recent in 2026, and is an investigator in 144 clinical trials, 48 of them ongoing. SLR score: 7,317 (community average: 125). How the SLR is computed.

LeadR Profile

Maria-Victoria Mateos Centro de Investigación del Cáncer Spain
7 317 ScienceLeadR Reputation 7317

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Immunology - Cardiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2002 - 2026
Source: PubMed

Complejo Hospitalario de Salamanca

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1299

Citations

Citations: 54 726 1st author: 181 Last author: 170 Unique author: 15

Main journals

Blood 384
CL LYMPH MYELOM LEUK 126
J Clin Oncol 120
Hemasphere 94
Haematologica 49

Best Journals

J Clin Oncol 78
N Engl J Med 24
Lancet Oncol 21

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial.
PMID 42790445 — progression-free survival, dexamethasone, neoplasms, disease progression, bortezomib, drug-related side effects and adverse reactions, multiple myeloma, pneumonia, sepsis, therapeutics, infections		Lancet Oncol Top journal20261
Author Correction: FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.
PMID 42901991 — molecular biology, multiple myeloma		Nat Med Top journal20260
T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis.
PMID 42844619 — cells, hematology, progression-free survival, probability, multiple myeloma, network meta-analysis, therapeutics, t-lymphocytes		J Hematol Oncol Top journal20260
Smoldering and Early Disease Interception.
PMID 42809692 — early intervention, educational, neoplasms, multiple myeloma, therapeutics		Cancer J20260
Exposure-response and dose simulation of belantamab mafodotin in combination with standards of care in patients with relapsed/refractory multiple myeloma.
PMID 42687822 — hematology, dexamethasone, probability, multiple myeloma		Haematologica20260

Clinical Studies 144

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 8 Study Chair: 3

By phase:

Phase 3 64
Phase 2 36
Phase 1 21
Phase 1/Phase 2 15
N/A 3
Phase 4 3
Phase 2/Phase 3 2

By status:

Completed 58
Active not recruiting 45
Recruiting 21
Terminated 10
Not yet recruiting 6
Unknown 3
Approved for Marketing 1

By type:

Interventional 141
Observational 2
Expanded Access 1

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 3
multicentric5to9 16
multicentricup10 119

Main Topics

Ongoing Clinical Trials

48 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 3 Randomized Study Comparing JNJ 79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
2025-523815-12-00 — multiple myeloma, lenalidomide, therapeutics		Phase 3Not yet recruiting2026
Cevostamab in Combination with Pomalidomide and Dexamethasone Versus Standard of Care in Patients with Previously Treated Multiple Myeloma
2025-524028-23-00 — safety, dexamethasone, multiple myeloma, therapeutics		Phase 3Not yet recruiting2026
A Phase 2 Open label Randomized Study to Evaluate GPRC5D related Oral Events
2023-506260-14-00 — dysgeusia, multiple myeloma		Phase 2Recruiting2025
Clinical trial for the use of a humanized CART directed against BCMA (ARI0002h) in patients with newly diagnosed primary plasma cell leukemia
2024-515053-21-00 — cells, safety, leukemia, plasma cell, plasma cells, leukemia, therapeutics, t-lymphocytes, plasma, car-t cell		Phase 2Recruiting2025
Phase II Open Label Single Arm Multicenter Study of Ciltacabtagene Autoleucel in High Risk Smoldering Multiple Myeloma
2023-510560-12-00 — multiple myeloma, smoldering multiple myeloma		Phase 2Not yet recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS